Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: Current knowledge, new research directions and therapeutic perspectives

Claudio Vernieri, Monica Milano, Marta Brambilla, Alessia Mennitto, Claudia Maggi, Maria Silvia Cona, Michele Prisciandaro, Chiara Fabbroni, Luigi Celio, Gabriella Mariani, Giulia Valeria Bianchi, Giuseppe Capri, Filippo de Braud

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

HER2-positive breast cancer (HER2 + BC)represents 15–20% of all BCs. In the last two decades, the introduction of monoclonal antibodies (MoAbs), tyrosine kinase inhibitors (TKIs)and antibody-drug conjugates (ADCs)directed against HER2 impressively improved patient prognosis in all disease stages. Yet, not all patients with limited-stage disease are cured, and HER2+ metastatic BC (mBC)remains an almost invariably deadly disease. Primary or acquired resistance to anti-HER2 therapies is responsible for most treatment failures. In recent years, several resistance mechanisms have been identified, such as impaired drug binding to HER2, constitutive activation of signaling pathways parallel or downstream of HER2, metabolic reprogramming or reduced immune system activation. However, only a few of them have been validated in clinical series; moreover, in the era of standard-of-care dual HER2 blockade, these mechanisms should be re-assessed and, in case, confirmed with anti-HER2 combinations. Defining the best strategies to delay or revert resistance to anti-HER2 treatments will be crucial to improve their clinical efficacy.

Original languageEnglish
Pages (from-to)53-66
Number of pages14
JournalCritical Reviews in Oncology/Hematology
Volume139
DOIs
Publication statusPublished - Jul 2019

Fingerprint

Therapeutic Human Experimentation
Breast Neoplasms
Standard of Care
Treatment Failure
Pharmaceutical Preparations
Protein-Tyrosine Kinases
Immune System
Therapeutics
Monoclonal Antibodies
Antibodies
Direction compound

Keywords

  • HER2-positive breast cancer
  • Lapatinib
  • Resistance mechanisms
  • T-DM1
  • T-DM1Pertuzumab
  • Trastuzumab

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

@article{1c4c7781474f426da7437e1141e1e18e,
title = "Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: Current knowledge, new research directions and therapeutic perspectives",
abstract = "HER2-positive breast cancer (HER2 + BC)represents 15–20{\%} of all BCs. In the last two decades, the introduction of monoclonal antibodies (MoAbs), tyrosine kinase inhibitors (TKIs)and antibody-drug conjugates (ADCs)directed against HER2 impressively improved patient prognosis in all disease stages. Yet, not all patients with limited-stage disease are cured, and HER2+ metastatic BC (mBC)remains an almost invariably deadly disease. Primary or acquired resistance to anti-HER2 therapies is responsible for most treatment failures. In recent years, several resistance mechanisms have been identified, such as impaired drug binding to HER2, constitutive activation of signaling pathways parallel or downstream of HER2, metabolic reprogramming or reduced immune system activation. However, only a few of them have been validated in clinical series; moreover, in the era of standard-of-care dual HER2 blockade, these mechanisms should be re-assessed and, in case, confirmed with anti-HER2 combinations. Defining the best strategies to delay or revert resistance to anti-HER2 treatments will be crucial to improve their clinical efficacy.",
keywords = "HER2-positive breast cancer, Lapatinib, Resistance mechanisms, T-DM1, T-DM1Pertuzumab, Trastuzumab",
author = "Claudio Vernieri and Monica Milano and Marta Brambilla and Alessia Mennitto and Claudia Maggi and Cona, {Maria Silvia} and Michele Prisciandaro and Chiara Fabbroni and Luigi Celio and Gabriella Mariani and Bianchi, {Giulia Valeria} and Giuseppe Capri and {de Braud}, Filippo",
year = "2019",
month = "7",
doi = "10.1016/j.critrevonc.2019.05.001",
language = "English",
volume = "139",
pages = "53--66",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer

T2 - Current knowledge, new research directions and therapeutic perspectives

AU - Vernieri, Claudio

AU - Milano, Monica

AU - Brambilla, Marta

AU - Mennitto, Alessia

AU - Maggi, Claudia

AU - Cona, Maria Silvia

AU - Prisciandaro, Michele

AU - Fabbroni, Chiara

AU - Celio, Luigi

AU - Mariani, Gabriella

AU - Bianchi, Giulia Valeria

AU - Capri, Giuseppe

AU - de Braud, Filippo

PY - 2019/7

Y1 - 2019/7

N2 - HER2-positive breast cancer (HER2 + BC)represents 15–20% of all BCs. In the last two decades, the introduction of monoclonal antibodies (MoAbs), tyrosine kinase inhibitors (TKIs)and antibody-drug conjugates (ADCs)directed against HER2 impressively improved patient prognosis in all disease stages. Yet, not all patients with limited-stage disease are cured, and HER2+ metastatic BC (mBC)remains an almost invariably deadly disease. Primary or acquired resistance to anti-HER2 therapies is responsible for most treatment failures. In recent years, several resistance mechanisms have been identified, such as impaired drug binding to HER2, constitutive activation of signaling pathways parallel or downstream of HER2, metabolic reprogramming or reduced immune system activation. However, only a few of them have been validated in clinical series; moreover, in the era of standard-of-care dual HER2 blockade, these mechanisms should be re-assessed and, in case, confirmed with anti-HER2 combinations. Defining the best strategies to delay or revert resistance to anti-HER2 treatments will be crucial to improve their clinical efficacy.

AB - HER2-positive breast cancer (HER2 + BC)represents 15–20% of all BCs. In the last two decades, the introduction of monoclonal antibodies (MoAbs), tyrosine kinase inhibitors (TKIs)and antibody-drug conjugates (ADCs)directed against HER2 impressively improved patient prognosis in all disease stages. Yet, not all patients with limited-stage disease are cured, and HER2+ metastatic BC (mBC)remains an almost invariably deadly disease. Primary or acquired resistance to anti-HER2 therapies is responsible for most treatment failures. In recent years, several resistance mechanisms have been identified, such as impaired drug binding to HER2, constitutive activation of signaling pathways parallel or downstream of HER2, metabolic reprogramming or reduced immune system activation. However, only a few of them have been validated in clinical series; moreover, in the era of standard-of-care dual HER2 blockade, these mechanisms should be re-assessed and, in case, confirmed with anti-HER2 combinations. Defining the best strategies to delay or revert resistance to anti-HER2 treatments will be crucial to improve their clinical efficacy.

KW - HER2-positive breast cancer

KW - Lapatinib

KW - Resistance mechanisms

KW - T-DM1

KW - T-DM1Pertuzumab

KW - Trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=85065156846&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065156846&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2019.05.001

DO - 10.1016/j.critrevonc.2019.05.001

M3 - Review article

C2 - 31112882

AN - SCOPUS:85065156846

VL - 139

SP - 53

EP - 66

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

ER -